Teva dumps pact with CureTech, takes $109M writeoff; AC Immune dumps Alzheimer's program on PhII failure;

 @FierceBiotech: Celsion shares routed after PhIII liver cancer study flops. News | Follow @FierceBiotech

@JohnCFierce: AstraZeneca's Soriot is going to have to do something bold, something dramatic, and something a little loony. In that order. | Follow @JohnCFierce

@RyanMFierce: Holland's health minister is sounding very German on drug pricing, wants to chop cost of Genzyme and Shire therapies. More | Follow @RyanMFierce

> Teva ($TEVA) has axed a cancer drug partnership with Israel's CureTech. Teva took a $109 million charge after deciding to drop the deal with CureTech on CT-011. The decision followed an analysis of clinical and biochemical data. Report

> AC Immune has slammed the brakes on one of its Alzheimer's programs. ACI-91, which was in-licensed, failed a small Phase II study for mild to moderate Alzheimer's. Far from improving measures of cognition and clinical function, patients demonstrated a drop on both scores. Release

> The U.K.'s BioIndustry Association is highlighting a new survey on the public's support for crowdfunding, which not coincidentally comes as the association is calling for government support for the initiative. Story

Pharma News

@FiercePharma: EMA sounds a bit perturbed about France's suspension of Diane-35. But it will review data when France asks. More | Follow @FiercePharma

 @AlisonBFierce: Life Technologies established an international flu network to develop a speedy monitoring system and better vaccine. News | Follow @AlisonBFierce

@EricPFierce: BASF says it has finally gotten the Pronova deal closed making it one of the largest fish oil producers in the world. Release | Follow @EricPFierce

> Novo meets 'sky-high' expectations with 18% sales growth. Report

> Genzyme's $176K Kynamro price undercuts its $250K-plus rival. Article

> Patent Cliff II: Nightmare on blockbuster street returns in 2015. News

Vaccines News

> MIT explores DNA vaccine delivery. Item

> Life establishes international flu network. More

> CDC: Adult vaccination rates 'unacceptably low.' Report

> FDA expands use of Pfizer's Prevnar 13. Article

> GSK, Biological E partner on childhood vaccine. Story

Pharma Manufacturing News

> Cargo theft up dramatically in Mexico. Item

> Sanofi's Genzyme looking hard at continuous manufacturing. News

> Biogen, Merck, Novartis, others have plants recognized for innovations. More

> Teva, P&G start on OTC plant in India. Story

And Finally… Star Scientific says that its experimental therapy anatabine looked promising in an animal model of multiple sclerosis. Release

 

Suggested Articles

Disarm Therapeutics signed on Alvin Shih, M.D., the former Retrophin R&D chief who went on to helm Enzyvant, as its full-time CEO.

Pact Pharma launched a phase 1 trial of a technology designed to attack solid tumors with CAR-T cells tailored to individual patients.

Intec's candidate uses a drug delivery system designed to improve on Merck’s Sinemet but was unable to beat the product in a late-phase test.